ストックスクリーナーアプリを入手
9.76
1.86%
-0.185
前日終値:
$9.945
開ける：
$10.06
24時間の取引高:
66,882
Relative Volume:
0.05
時価総額：
$87.94M
収益：
$23.14M
当期純損益:
$-9.47M
株価収益率:
-11.06
EPS:
-0.8827
ネットキャッシュフロー:
$-25.88M
1週間 パフォーマンス:
-16.22%
1か月 パフォーマンス:
-1.01%
6か月 パフォーマンス:
-28.60%
1年 パフォーマンス:
+2.95%
1日の値動き範囲:
$9.355
$10.06
1週間の範囲:
$9.355
$11.86
52週間の値動き範囲:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
名前
Atara Biotherapeutics Inc
セクター
電話
805-623-4211
住所
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
9.76 | 87.94M | 23.14M | -9.47M | -25.88M | -0.8827 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-13 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-11-09 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-07-20 | ダウングレード | Citigroup | Neutral → Sell |
| 2022-07-13 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-07-13 | ダウングレード | Stifel | Buy → Hold |
| 2022-05-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-05-13 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-12-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-12-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-30 | 開始されました | Evercore ISI | Outperform |
| 2020-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-23 | アップグレード | Citigroup | Neutral → Buy |
| 2019-11-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-09-27 | ダウングレード | Goldman | Neutral → Sell |
| 2019-09-16 | ダウングレード | Jefferies | Buy → Hold |
| 2019-06-04 | アップグレード | Citigroup | Sell → Neutral |
| 2019-05-30 | 開始されました | ROTH Capital | Buy |
| 2019-05-23 | 開始されました | Stifel | Buy |
| 2019-01-23 | 開始されました | Mizuho | Buy |
| 2018-04-10 | 開始されました | JP Morgan | Overweight |
| 2018-03-16 | 開始されました | Guggenheim | Neutral |
| 2018-03-05 | 繰り返されました | Jefferies | Buy |
| 2018-02-28 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | ダウングレード | Citigroup | Neutral → Sell |
| 2018-01-03 | アップグレード | Citigroup | Sell → Neutral |
| 2017-10-06 | 再開されました | Goldman | Neutral |
すべてを表示
Atara Biotherapeutics Inc (ATRA) 最新ニュース
ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - AOL.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect - ACCESS Newswire
Atara Biotherapeutics Inc. (ATRA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - AOL.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
2026-07-07 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation | NDAQ:ATRA | Press Release - Stockhouse
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Atara Biotherapeutics (ATRA) interim CFO Kevin Sarney files initial Form 3 - Stock Titan
Atara Biotherapeutics (ATRA) 10K Form and Latest SEC Filings 2026 - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation - ACCESS Newswire
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
ATRAAtara Biotherapeutics Inc Latest SEC Filings - Finviz
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out - ACCESS Newswire
ATRA Stockholders Have Opportunity to Lead Atara Biotherapeutics - The National Law Review
Discipline and Rules-Based Execution in ATRA Response - Stock Traders Daily
ATRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out - ACCESS Newswire
ATRA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Atara Biotherapeutics, Inc.(NasdaqGS:ATRA) dropped from Russell 3000E Value Benchmark - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect - ACCESS Newswire
Atara Biotherapeutics Inc Actuals & Estimates (GETTEX:AT20) - TradingView
Atara Biotherapeutics, Inc.(NasdaqGS:ATRA) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Atara Biotherapeutics Inc Actuals & Estimates (SWB:AT20) - TradingView
ATRA News | ATARA BIOTHERAPEUTICS INC (NASDAQ:ATRA) - ChartMill
Atara Biotherapeutics (NASDAQ: ATRA) appoints CRCFO consultant as interim CFO - Stock Titan
Atara Biotherapeutics Inc Actuals & Estimates (NASDAQ:ATRA) - TradingView
Atara appoints Kevin G. Sarney as interim CFO; Yanina Grant-Huerta to depart - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
ATRA Forecast — Price Target — Prediction for 2027 - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Atara Biotherapeutics Inc (ATRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Atara Biotherapeutics Inc (ATRA) Institutional Confidence - TradingKey
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Behavioral Patterns of ATRA and Institutional Flows - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect - ACCESS Newswire
Atara Biotherapeutics Inc (ATRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Atara Biotherapeutics Inc (ATRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Atara Biotherapeutics Inc (ATRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Atara Biotherapeutics Inc (ATRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Atara Biotherapeutics Inc (ATRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Atara Biotherapeutics Inc (ATRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atara Biotherapeutics Inc (ATRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Atara Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Director Cherry Brian N - Moomoo
Atara Biotherapeutics (ATRA) director awarded 24,000 restricted stock units - Stock Titan
Atara Biotherapeutics (NASDAQ: ATRA) director reports 38,320-share common stock holding - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Atara Biotherapeutics Adds Independent Director to Board - The Globe and Mail
Atara Biotherapeutics appoints Brian Cherry to board By Investing.com - Investing.com Australia
Atara Biotherapeutics appoints Brian Cherry to board - Investing.com
New Atara (NASDAQ: ATRA) director and 2026 shareholder vote outcomes - Stock Titan
Atara Biotherapeutics Inc (ATRA) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):